Leads Biolabs receives IND approval from the National Medical Products Administration for the treatment of metastatic colorectal cancer.
August 3, 2026
Source: drugdu
26
On August 3, Leads Biolabs announced on the Hong Kong Stock Exchange that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for its independently developed candidate drug, Verizon (opatidisulfimab, a PD-L1/4-1BB bispecific antibody, LBL-024), for the treatment of metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multicenter Phase Ib/II study designed to evaluate the safety and efficacy of Verizon in combination with other drugs for the treatment of mCRC.
https://finance.eastmoney.com/a/202608033829221843.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Submission of supplementary materials for serum-free iterative rabies vaccine completed. August 3, 2026
- Hengrui Medicine’s HER3 ADC “Ruikang Luzettotatumab” has been submitted for marketing approval. August 3, 2026
- Boston Scientific is investing $5 billion to begin “slimming down”. August 3, 2026
- While Da Vinci Remains in “Remote Control” Mode, Cornerstone Robotics Has Evolved to “Autonomous Operation”—A Technological Leap for Domestic Surgical Robots July 31, 2026
- Carbamazepine Extended-Release Tablets (II) Receive Drug Registration Certificate July 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
